Abercrombie & Fitch Co. vs Baxter International Inc — how do they compare? Abercrombie & Fitch Co. trades at $118.27 (market cap $5.27B), while Baxter International Inc trades at $27.61 (market cap $14.36B). The key difference: Baxter International Inc is far larger — about 2.7× Abercrombie & Fitch Co.'s market cap, and Baxter International Inc pays a 0.14% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.
| ANF | BAX | |
|---|---|---|
Market Cap | $5.27B | $14.36B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $28.35 |
52-Week Low | $65.61 | $15.80 |
Enterprise Value | $5.94B | $21.88B |
Dividend Yield | — | 0.14% |
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $112.62, up 1.94% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $4.95B and net income of $566.22M, achieving consistent earnings beats in recent quarters. Valuation remains attractive with P/E of 10.89 and EV/EBITDA of 6.54, while profitability metrics show impressive ROE of 39.04% and net margin of 9.34%.
ANF presents a compelling investment case with strong operational performance and reasonable valuation, though technical indicators show overbought conditions. Key risks include retail sector volatility and potential growth headwinds in EMEA markets. Analyst consensus leans neutral with 50% hold ratings, while institutional ownership trends show continued interest from major funds.
Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.
The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.
Trailing returns across standard periods
Latest headlines on both assets
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →